N. Clarke, A. Armstrong, A. Thiery-Vuillemin, M. Oya, N. Shore, E. Loredo, G. Procopio, Juliana J. de Menezes, G. Girotto, Ç. Arslan, N. Mehra, F. Parnis, E. Brown, F. Schlürmann, J. Joung, M. Sugimoto, J. Virizuela, U. Emmenegger, J. Navrátil, G. Buchschacher, C. Poehlein, E. Harrington, C. Desai, Jinyu Kang, F. Saad
2022.6.3NEJM Evidence
tlooto Summary
Patients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair gene mutation status, received either abiraterone and olaparib or abiraterone and placebo in the first-line setting.
Abstract
Abiraterone and Olaparib for Metastatic Prostate CancerPatients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair gene mutation status, received either abiraterone and olaparib or abiraterone and placebo in the first-line setting. Imaging-based progression-free survival was 24.8 months for patients treated with abiraterone and olaparib versus 16.6 months for those receiving abiraterone alone.
Citation format
CLARKE, N., et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evidence, 2022, 1 9: EVIDoa2200043.